RNA NANOPARTICLES

Products by Application

  • Cell Targeting
    View
  • Cancer in Vitro
    View
  • Cancer in Vivo:
    View
  • Chemical Modification
    View
  • Fluorescent Labeling
    View
  • Tumor Targeting
    View

Customized Products

Custom Design: Select the ligand for targeting specific cancer cells and desired therapeutic modules (miRNA, anti-miRNA, siRNA or
chemical drug) for your research needs. We can prepare the required RNA nanoparticles with high quality and in large scale for

General Design of RNA Nanoparticles

  • SCAFFOLD

    Multi-Way Junction 2′-Fluoro RNA is highly thermodynamically and enzymatically stable and remains intact at ultra-low concentrations in blood circulation. It is an ideal scaffold for drug delivery. RNA scaffolds are available of various shapes and sizes.

  • TARGETING LIGAND

    Nucleic acide-based aptamers and small chemical ligands can be conjugated to either termini of the scaffold to achieve specific targeting. The high thermodynamic stability of the junction scaffolds ensures correct folding and function of aptamers.

  • THERAPEUTIC MODULE

    Small nucleic acid based therapeutic candidates, such as miRNA, antimiRNA, siRNA, CpG DNA immune modulatores, and chemical drugs can be easily conjugated to the junction scaffold, with authentic functinalities.

  • IMAGING MODULE

    Fluorescent or radioactive molecules can be conjugated to the scaffold as an imaging module. Near infrared labeling of RNA nanoparticles allows for real time monitoring of bio-distribution in vivo using IVIS imaging system.

The functional Modules can be selected from below with any combination or stoichiometry according to your project requirement:

1. Targeting Ligand: aptamers or chemical ligand
2. Imaging Module: Fluorescent or radiolabeled
3. Therapeutics Module: siRNA, miRNA, anti-miRNA, chemical drugs

Advantages of
RNA Nanoparticles
for Therapy

1) Negative charge desallows nonspecific permeation of negatively charged cell membranes

2) Controlled synthesis provides defined structure and stoichiometry

3) Multi-valency allows combination therapy and simultaneous targeting and detection

4) Targeted delivery allows receptor mediated endocytosis

5) Advantageous size (10 – 40 nm)

6) Extended in vivo half-life (5-12 hr compared to 15-45 min for siRNA)

7) Avoidance of antibody induction (protein-free) allows repeated treatment for chronic diseases.

8) Favorable pharmacokinetic profile in mice:

– PK (T1/2) : 5-10 hr compared to 0.25-0.76 hr of siRNA

– Clearance (Cl): <0.13 l/kg/hr

– Volume of distribution (V(d)): 1.2 l/kg

– Does not induce interferon response or cytokine

– Repeated IV up to 30 mg/kg do not result in toxicity

9) RNA nanoparticles are classified as chemical drugs rather than biologics. This classification facilitates drug approval.

AFM Image of RNA-3WJ Nanoparticles

RNA Nanoparticles for Cancer Targeting in vivo

Get Industry
Expert Consultation

For Investors

Advantages of RNA Nanoparticles for Therapy
  • -Negative charge disallows nonspecific permeation of negatively charged cell membrane

  • -Controlled synthesis provides defined structure and stoichiometry

  • -Multi-valency allows combination therapy and simultaneous targeting and detection

  • -Targeted delivery allows receptor mediated endocytosis

  • -Advantageous size (10 – 40 nm)

  • -Extended in vivo half-life (5-12 hr compared to 15-45 min for siRNA)

  • -Avoidance of antibody induction (protein-free) allows repeated treatment for chronic diseases

  • - Favorable pharmacokinetic profile in mice:

    • Half-life (T1/2) : 5-10 hr compared to 0.25-0.76 hr of siRNA counterpart;

    • Clearance (Cl): <0.13 l/kg/hr,

    • Volume of distribution (V(d)): 1.2 l/kg;

    • Does not induce interferon (IFN) response or cytokine production;

    • Repeated IV administrations of up to 30 mg/kg do not result in toxicity.

  • - RNA nanoparticles are classified as chemical drugs rather than biologics. This classification facilitates drug approval.

Contact Us